Dual Agenzia – Curaleaf education

Articles Cancer treatment disorder Cannabidiol (CBD)Tetraidrocannabinol (THC)

24 June 2024

Help from cannabinoids against chemotherapy-induced nausea and vomiting

An Australian study evaluated the efficacy and safety of a THC:CBD extract in the prevention…

Dual Agenzia

Love0

Articles Cannabidiol (CBD)Neurological disorders Pain therapy Tetraidrocannabinol (THC)

15 May 2024

The potential usefulness of endocannabinoids in the treatment of headaches

New treatments are needed to counteract the often debilitating effects of headaches and migraines; the…

Dual Agenzia

Love0

Articles Cannabidiol (CBD)Neurological disorders Pain therapy Psychological disorders Tetraidrocannabinol (THC)

14 May 2024

Cannabinoids for chronic pain: when and how to use them

A Canadian working group has conducted a literature review and has drawn up clinical practice…

Dual Agenzia

Love0

Articles Cannabidiol (CBD)Neurological disorders Pain therapy Tetraidrocannabinol (THC)

23 April 2024

Cannabinoids for treatment-resistant epilepsy: what is known

Several studies have assessed the efficacy, safety and tolerability of CBD in addition to drug…

Dual Agenzia

Love0

Articles Cannabidiol (CBD)Neurological disorders Pain therapy Psychological disorders Tetraidrocannabinol (THC)

28 December 2023

Cannabinoids for multiple sclerosis symptoms

Some literature reviews have provided a general overview of the available data on the role…

Dual Agenzia

Love0

Articles Cannabidiol (CBD)Neurological disorders Pain therapy Tetraidrocannabinol (THC)

30 November 2023

Cannabis for the treatment of chronic pain: the data in favour are increasing

New studies from the UK Registry point to the fact that various formulations may improve…

Dual Agenzia

Love0

© 2024 Curaleaf education.
Progetto editoriale di Curaleaf International Pharma Sagl - Via Trevani, 1 - 6600 - Locarno - Svizzera
Privacy & Cookie Policy